- Coles Donate $31 Million to Cleveland Clinic Cole Eye Institute
Jeffrey A. Cole and his wife, Patricia O’Brien Cole, awarded a transformational gift to continue their philanthropic legacy at the Cleveland Clinic Cole Eye Institute. This $31 million commitment will help Cole Eye Institute expand its clinical and surgical capabilities, and enhance its research and educational mission. This will be accomplished primarily through a future expansion to the existing Cole Eye Institute, which would be named the “Jeffrey and Patricia Cole Building.” Read more.
- EyeGate Releases Data from Third Stage of Phase Ib/IIa Clinical Trial
EyeGate Pharmaceuticals announced promising data from the third stage of its Phase Ib/IIa trial assessing its lead product candidate, iontophoretic EGP-437, for the treatment of ocular inflammation and pain in post-surgical cataract patients. Stage three of this multicenter, open-label clinical trial enrolled 30 subjects who underwent cataract surgery with implantation of a posterior chamber intraocular lens. Subjects were divided into three cohorts and received iontophoretic doses of EGP-437 at 4.5 milliampere-minutes, 14 mA-min or a placebo at 14 mA-min. Subjects in the EGP-437 14 mA-min cohort were administered treatments on day zero (preoperative), day one and day four. The other two cohorts were administered treatments on day 0 (postoperative), day one and day four. The potential for an additional treatment on day seven at the physician's discretion was allowed in all three cohorts. A positive response, determined by a reduction in anterior chamber cell count, was observed in cases in both of the EGP-437 treatment arms. Those who were administered 4.5 mA-min dosing (3 mA for 1.5 minutes) demonstrated the greatest benefit, with 30 percent and 80 percent of subjects at day 14 and day 28, respectively, achieving complete reduction or an ACC count of zero. Read more.
- Aerie Completes Enrollment of Mercury 2 Phase III Registration Trial
Aerie Pharmaceuticals completed patient enrollment in the company's second Phase III registration trial (Mercury 2) of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel, once-daily eye drop being tested for its ability to lower intraocular pressure in individuals with glaucoma or ocular hypertension. The solution is a fixed-dose combination of Aerie's drug Rhopressa (netarsudil ophthalmic solution) 0.02% and latanoprost, a widely prescribed prostaglandin analog. Total patient enrollment has exceeded the 690 individuals needed for the three-arm study designed to demonstrate superiority of Roclatan solution to each of its two components, all dosed once-daily in the evening. Read more.
- Dr. Link Joins Allegro Board
Allegro Ophthalmics, a biotechnology company focused on the development of novel therapies to treat vitreoretinal diseases, announced that William J. Link, PhD, was elected to Allegro's board of directors. Dr. Link is co-founder and a managing director of Versant Ventures, a global health care investment firm where he specializes in early-stage investing in medical devices. Prior to Versant, Dr. Link was a general partner at Brentwood Venture Capital. With more than two decades of operations experience in the health-care industry, Dr. Link has a proven record of building and managing large, successful medical product companies, including Chiron Vision where he was co-founder, chairman and CEO until it was sold to Bausch + Lomb in 1997. In addition, he founded and served as president of American Medical Optics. Read more.
- AGTC Appoints Dr. Goldstein as Chief Medical Officer
Applied Genetic Technologies Corp. announced the appointment of Michael Goldstein, MD, MBA, as chief medical officer. Prior to joining, Dr. Goldstein held roles of increasing responsibility with Eleven Biotherapeutics, including chief medical officer and vice president of clinical research, where he helped bring a novel treatment for dry-eye disease from early research to a completed trial. Since 2002, he has served as co-director of the cornea and external disease service and assistant professor of ophthalmology at the New England Eye Center. Previously, he was director of refractive surgery service and assistant professor of ophthalmology at the University of Florida College of Medicine. Read more.
- Ruling Affirms Paragon's Patent Claim
Paragon BioTeck announced the United States Patent and Trademark Office affirmed claims made by Paragon in the patent for its R-phenylephrine hydrochloride formulation. In late 2015, Altaire Pharmaceuticals sought to invalidate Paragon's patent that claims a method of maintaining purity of the formulation. In the fourth written decision by the Patent Trial and Appeals Board, the ruling affirmed that the petition by Altaire Pharmaceuticals was without merit. The patent ruling reinforces the science underlying the formulation of Paragon's phenylephrine hydrochloride ophthalmic solution and substantiates the operational philosophy of the company. Read more.
- OWL Welcomes New Board Members
OWL, an association of interdisciplinary ophthalmic professionals dedicated to driving innovation and patient care by advancing diversity in leadership, named the following new members to its board of directors.
- Michael Ackermann, PhD, is vice president, neurostimulation at Allergan, and oversees all operations at the company’s San Francisco location. Dr. Ackermann is also co-founder of Oyster Point Pharmaceuticals, which is focused on developing novel assets for the treatment of ophthalmic disease.
- Taryn Conway, director of marketing, Dry Eye Franchise, Allergan, leads the strategic development of dry-eye marketing, long-term strategic and life cycle management planning, and oversees implementation of key initiatives for driving continued franchise growth.
- Candace Simerson is president of Minnesota Eye Consultants, P.A., an ophthalmology practice specializing in refractive surgery with subspecialists in cornea, glaucoma and ophthalmic plastics. In addition to more than 25 years of experience in medical practice management, Simerson is a Certified Ophthalmic Executive and a Certified Medical Practice Executive.
- John Vukich, MD, is clinical adjunct assistant professor of ophthalmology and visual science, University of Wisconsin-Madison School of Medicine. Additionally, Dr. Vukich is president of the American-European Congress of Ophthalmic Surgery, is on the governing board for the American Society of Cataract and Refractive Surgery where he serves as chair of the Refractive Clinical Committee, and is a member of the Annual Program Committee for the American Academy of Ophthalmology.